Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2

All three cohorts show separation from placebo with statistically significant difference from placebo at day 28

Read more at globenewswire.com